Q2 2026 13F · SEC CIK 1527166
Carlyle Group Inc.
Hedge fundFiled 2026-08-07 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $10.0B
- Reported positions
- 19
- Top holdings a year, 3 yrs
- -13.7%
- Assets under management
- $283.8B
Carlyle Group Inc. is a hedge fund that reported 19 positions worth $10.0B in its Q2 2026 13F, filed 2026-08-07. Its largest holdings were Medline Inc (MDLN, 73.8%), Standardaero Inc (SARO, 25.3%), Phathom Pharmaceuticals Inc Com (PHAT, 0.4%). A portfolio copying its top holdings returned -13.7% a year over the last 3 years, against 20.4% for the S&P 500.
Carlyle Group Inc. holdings all 19 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| MDLNMedline Inc | 73.8% | +0.0% | $7.4B |
| SAROStandardaero Inc | 25.3% | +0.0% | $2.5B |
| PHATPhathom Pharmaceuticals Inc Com | 0.4% | +0.0% | $37.9M |
| INVHInvitation Homes Inc | 0.2% | -0.2% | $20.0M |
| PONYPony Ai Inc | 0.2% | +0.0% | $16.4M |
| GETYQGetty Images Holdings Inc | 0.1% | +0.0% | $5.4M |
| 85209E208Spruce Biosciences Inc | 0.0% | +0.0% | $2.1M |
| SPWRSunPower Inc | 0.0% | +441.1% | $1.6M |
| ACETAdicet Bio Inc | 0.0% | +0.0% | $1.6M |
| FWRDForward Air Corp | 0.0% | +0.0% | $1.4M |
| OKUROnkure Therapeutics Inc | 0.0% | +0.0% | $1.2M |
| DNUTKrispy Kreme Inc | 0.0% | +0.0% | $1.2M |
| QTTBQ32 Bio Inc | 0.0% | -94.5% | $769K |
| REPXRiley Exploration Permian in | 0.0% | — | $530K |
| NBISNebius Group N.v. | 0.0% | — | $510K |
| HOODRobinhood Mkts Inc | 0.0% | +40.2% | $475K |
| JSPRJasper Therapeutics Inc | 0.0% | +0.0% | $449K |
| NABLN-Able Inc | 0.0% | +0.0% | $344K |
| METCRamaco Resources | 0.0% | — | $288K |
What Carlyle Group Inc. bought and sold in Q2 2026, against Q1 2026.
New positions
- REPX Riley Exploration Permian in0.0% of 13F
- NBIS Nebius Group N.v.0.0% of 13F
- METC Ramaco Resources0.0% of 13F
Added to
- SPWR SunPower Inc+441.1% shares
- HOOD Robinhood Mkts Inc+40.2% shares
Reduced
- QTTB Q32 Bio Inc-94.5% shares
Sold out
- CUBE Cubesmartwas 0.1%
- HTFL Heartflow Incwas 0.0%
- SYRE Spyre Therapeuticswas 0.0%
- XCUR Exicure Incwas 0.0%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- -8.6% /yr
- S&P 500 +20.1%
- 3 years
- -13.7% /yr
- S&P 500 +20.4%
- 5 years
- -15.8% /yr
- S&P 500 +16.8%
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $10.0B | 19 |
| Q1 2026 | $10.6B | 20 |
| Q4 2025 | $13.6B | 20 |
| Q3 2025 | $4.3B | 17 |
| Q2 2025 | $5.0B | 20 |
| Q1 2025 | $3.8B | 23 |
| Q4 2024 | $4.1B | 27 |
| Q3 2024 | $954.2M | 26 |
| Q2 2024 | $1.1B | 31 |
| Q1 2024 | $1.6B | 32 |
| Q4 2023 | $2.1B | 25 |
| Q3 2023 | $2.3B | 25 |
Questions about Carlyle Group Inc.'s portfolio
What stocks does Carlyle Group Inc. own?
Carlyle Group Inc.'s latest 13F, for Q2 2026 and filed Aug 7, 2026, lists 19 positions worth $10.0B. The largest are Medline Inc (MDLN) at 73.8%, Standardaero Inc (SARO) at 25.3%, Phathom Pharmaceuticals Inc Com (PHAT) at 0.4%, Invitation Homes Inc (INVH) at 0.2% and Pony Ai Inc (PONY) at 0.2%.
What did Carlyle Group Inc. buy last quarter?
In Q2 2026, Carlyle Group Inc. added a new position in Riley Exploration Permian in (REPX), a new position in Nebius Group N.v. (NBIS), a new position in Ramaco Resources (METC), SunPower Inc (SPWR) (+441.1% shares) and Robinhood Mkts Inc (HOOD) (+40.2% shares), compared with its Q1 2026 filing.
What did Carlyle Group Inc. sell last quarter?
In Q2 2026, Carlyle Group Inc. sold all of Cubesmart (CUBE), sold all of Heartflow Inc (HTFL), sold all of Spyre Therapeutics (SYRE), sold all of Exicure Inc (XCUR) and Q32 Bio Inc (QTTB) (-94.5% shares), compared with its Q1 2026 filing.
How has Carlyle Group Inc.'s portfolio performed?
A portfolio copying Carlyle Group Inc.'s 20 largest 13F holdings each quarter, from the day each filing was public, returned -13.7% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: -8.6% against +20.1%. Over 5 years: -15.8% a year against +16.8%.
When is Carlyle Group Inc.'s next 13F filing due?
13F filings are due 45 days after each quarter ends. Carlyle Group Inc.'s filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Carlyle Group Inc. manage?
Carlyle Group Inc. reported $283.8B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $10.0B.